AKT1 and neoplasm: Although we have attempted to perform these studies in a rigorous fashion, several possible caveats exist: (i) a very rare tumor cell subpopulation (ie, less than the assay sensitivity of ~2%) may express functional EpoR, albeit with questionable clinical relevance, (ii) the incidence of tumors with EpoR function may be too infrequent to have been detected in this study, and (iii) the actual receptor responding to rHuEpo is unique and does not utilize PI3K/AKT, MAPK, or STAT5 for signaling.